Note from the editor

DeepCure is building a different kind of AI biotech company. DeepCure’s AI is harnessing the power of a molecular foundry to synthesize and assay compounds from the world’s largest small molecule library.DeepCure is a biotech company with preclinical immunology and oncology assets looking for partners to collaborate on current and new small molecule discovery programs.Deepcure is building a platform that focuses on what drug hunters need. The platform leverages AI to predict binding, selectivity, and other pharmacological properties for optimization, an ultra-large chemical library (10^18 compounds), and a molecular foundry to automate synthesis and assays. DeepCure was founded at the Massachusetts Institute of Technology (MIT) to accelerate breakthroughs in drug discovery and has raised $47 million from investors, including Morningside. DeepCure is a world-class team of drug discovery and computer scientists headquartered in Boston, MA.